Megan Lynch/LinkedIn
Jun 16, 2026, 16:17
Megan Lynch: Thrilled to Join AstraZeneca
Megan Lynch, Global Product Leader, Cell Therapy Enterprise at AstraZeneca, shared a post on LinkedIn:
“I’m thrilled to share that I’m joining AstraZeneca as a Global Product Leader, Cell Therapy Enterprise.
Cell therapy is transforming how we treat patients across hem/onc, autoimmune, and rare disease.
Getting innovative medicines to patients and providers has always been my north star and I can’t wait to dig in.
Thank you to Margie Li, Margaret DiGuardo, Carsten Linnemann, Craig Maxwell, and Eva Piqué for your partnership throughout this process — I’m looking forward to what we’ll build together.
Here’s to what’s next.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 12:02Hajra Malik: Bridging Language Gaps in Hematology With AI
-
Sep 29, 2026, 11:57Joan Montaner: Can Blood Test Identify Intracerebral Hemorrhage Within Minutes?
-
Sep 29, 2026, 11:43From Years Without Answers to Life With Hemophilia Care – WFH
-
Sep 29, 2026, 11:32Sara Al Dallal: Transforming Hemophilia Care Across the Gulf
-
Sep 29, 2026, 11:21Richard Davis: Rapid Rescue in Massive Pulmonary Embolism
-
Sep 29, 2026, 11:14Nissan Brown: Every Step Counts for the Hemophilia Community
-
Sep 29, 2026, 11:03Zain Khalpey: SINGLE AF Adds New Evidence to the Anticoagulation Debate
-
Sep 29, 2026, 10:54How Does Haemophilia Affect Motor Development in Infants? – EAHAD
-
Sep 29, 2026, 10:49Alison Davey: The Vital Role of Community Support in Bleeding Disorders